Approximately 20% of COVID-19 patients with mild-moderate disease progress to severe-critical disease, and this percentage increases to 40% for the high-risk subgroup ≥65 years of age with comorbidities or laboratory parameters indicative of systemic inflammation, such as high levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), and ferritin or dysfunction of the coagulation system, as evidenced by elevated D-dimer levels (Uckun, 2020a). This evidence concerns the gene CRP and COVID-19.